Evidence map›Paper›PMID 36862207›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2023

Astatine-211 for PSMA-targeted α-radiation therapy of micrometastatic prostate cancer: a sustainable approach towards precision oncology.

Rubel Chakravarty, Xiaoli Lan, Sudipta Chakraborty, Weibo Cai

Abstract readEditorialComment
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Effective treatment of human prostate carcinoma xenografts with Single-Dose PSMA-targeted [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Article
  3. In vivo stableEJNMMI radiopharmacy and chemistry · 2024
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. A third generation PSMA-targeted agent [Nuclear medicine and biology
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Rubel ChakravartyRadiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India. rubelc@barc.gov.in.
Xiaoli LanDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Sudipta ChakrabortyRadiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India.
Weibo CaiDepartments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, USA. wcai@uwhealth.org.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
NCI NIH HHS P30 CA014520
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AstatineProstatic NeoplasmsAntigens, SurfaceHumansMaleNeoplasm Recurrence, LocalPrecision MedicineAntigens, SurfaceAstatineAstatine-211

Identifiers

PMID36862207
PMCPMC10200747

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.